We are live on
!
Find out more
GKIM
GW&K Investment Management Portfolio holdings
AUM
$11.3B
1-Year Est. Return
31.98%
This Fund
S&P 500
This Quarter
Est. Return
+25.52%
1 Year Est. Return
+31.98%
3 Year Est. Return
+79.76%
5 Year Est. Return
+101.81%
10 Year Est. Return
+512.72%
AUM
$9.53B
AUM Growth
+$1.89B
(+25%)
Cap. Flow
+$270M
Cap. Flow
% of AUM
2.83%
Top 10 Holdings %
Top 10 Hldgs %
11.36%
Holding
417
New
23
Increased
169
Reduced
161
Closed
41
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Medpace
MEDP
|
+$39.8M |
| 2 |
Endava
DAVA
|
+$35.7M |
| 3 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$32.6M |
| 4 |
Halozyme
HALO
|
+$30.3M |
| 5 |
Azenta
AZTA
|
+$29M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
QuidelOrtho
QDEL
|
+$67.2M |
| 2 |
VRTU
Virtusa Corporation
VRTU
|
+$45.8M |
| 3 |
SiteOne Landscape Supply
SITE
|
+$40.6M |
| 4 |
Insulet
PODD
|
+$37.5M |
| 5 |
Five Below
FIVE
|
+$25.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 17.76% |
| 2 | Technology | 15.98% |
| 3 | Industrials | 14.75% |
| 4 | Consumer Discretionary | 13.32% |
| 5 | Financials | 12.96% |
Similar funds
BHCM
VLKIM
ERSOT
DCP
DWM
GIM
MIFH
GW&K Investment Management's Q4 2020 Portfolio in Review
As of Q4 2020, GW&K Investment Management held 417 positions worth $9.53B, up 25% from $7.64B the previous quarter. Its ten largest holdings account for 11% of the portfolio.
GW&K Investment Management's Q4 2020 filing shows 23 new, 169 increased, 161 reduced and 41 closed positions. Its largest new stake was Medpace: 315,843 shares worth $44M. The largest sale was QuidelOrtho, an estimated $67.2M.
By sector, the portfolio is most concentrated in Healthcare at 18% of assets, up from 18% a quarter earlier, followed by Technology and Industrials.
- GW&K Investment Management's largest Q4 2020 buy was Medpace: 315,843 shares worth $44M.
- GW&K Investment Management added most to Endava in Q4 2020, an estimated $35.7M increase.
- GW&K Investment Management's biggest Q4 2020 reduction was QuidelOrtho, cutting an estimated $67.2M.
- GW&K Investment Management fully exited Aimmune Therapeutics in Q4 2020, selling an estimated $10.2M.
- GW&K Investment Management's ten largest holdings make up 11% of its $9.53B portfolio in Q4 2020.
- GW&K Investment Management opened 23 new positions and closed 41 in Q4 2020.
- GW&K Investment Management's portfolio value rose 25% quarter-over-quarter to $9.53B.
Based on GW&K Investment Management's 13F filing for Q4 2020, filed 5 Feb 2021.